The following information is from Children’s Health Defense.
Pharmaceutical giant Gilead recalled one batch of its COVID-19 antiviral drug Veklury, the brand name for Remdesivir, after glass particles were discovered in vials of the drug. A company investigation, prompted by a customer complaint, confirmed the presence of glass, according to the company recall notice posted on the US Food and Drug Administration (FDA) website.
Gilead distributed the batch, identified as Veklury lot No. 47035CFA, across the US beginning on July 16. The batch isn’t set to expire until November 2025. If a product containing glass is injected, the company warned in the recall notice, it can potentially lead to serious health issues, including stroke and even death.
This is not the first time glass particles have been found in the COVID drug. In December 2021, Gilead confirmed glass contamination in two lots of Veklury after a similar customer complaint. The repeated contamination incidents have raised concerns about the safety protocols in place for the manufacturing of this widely used COVID-19 treatment.
To read the full article, click here.
Glass particles in anything that enters anyone’s body is not good and Gilead did the correct thing by recalling the contaminated vials of medication. However the glass particles contained in the Remdesivir is not the most pressing reason to recall the medication. The Fauci supported Covid Medication does not work and actually damages kidneys and ultimately kills a person with continued use. That would be a better reason for recalling Remdesivir.